Gunderson Dettmer

Nate is a corporate and securities associate.

Nate represents start-up, emerging growth and public life sciences and technology companies and is passionate about working with companies that are developing scientific and technological innovations that will improve lives, transform business and tackle the world’s biggest problems.

His practice spans the entire corporate lifecycle, from formation through liquidity, and he regularly serves as principal outside or general counsel to his clients. Nate is broadly experienced in business formation and entity selection, deal structuring, equity and debt financing transactions, restructuring and spin-outs, general corporate and governance matters, M&A events and public offerings.

He also represents many of the leading seed, venture capital and growth equity investment funds in their investment transactions. Prior to joining Gunderson Dettmer, Nate was a private equity and mergers & acquisitions associate in the Boston and San Francisco offices of Ropes & Gray LLP.

Nate lives in the Bay Area with his wife and labradoodle, loves skiing, biking (mountain biking, gravel and road), and hiking.

General Corporate Counseling and Venture Financings

Moonwalk Biosciences with its formation and $57 million Series A Financing
Radar Therapeutics in its $13.4 million Series Seed financing
BillionToOne in its $130 million Series D financing, $125 million Series C financing, $48.5 million equity and $35 million debt financing
Alamar Biosciences in its $128 million Series C financing, $80 million Series B financing and spin-out of Attovia Therapeutics
Neuron23 in its $100 million Series C financing
Ancora Biotech LLC in its formation and $60 million Series A financing co-lead by Lightspeed Venture Partners and SR One
Star Therapeutics LLC in its $90 million Series C financing led by Sofinnova and spin-out of Electra Therapeutics
Electra Therapeutics in its $84 million Series B financing
Pro Shop its formation, $20 million Series A financing and partnership with the PGA Tour
Imply Data in its $100 million Series D financing

Growth Equity

Healthquest Capital in its investment in American Oncology Network in connection with American Oncology Network’s up-C reorganization and de-SPAC transaction
PFM Health Sciences as lead investor in Metagenomi’s $175 million Series B financing
Sixth Street Partners as lead investor in the $830 million growth equity financing in Caris Life Sciences*
Silver Lake Partners in its investment in Stripe*
Silver Lake Partners in its $400 million growth equity investment in EverCommerce*

Mergers & Acquisitions

TeneoTwo in its sale, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, to Astazeneca for up to $1.27 billion
Miroculus in its sale to Integra Biosciences
Gilead Sciences*, Inc. in:
its $1.74 billion exclusive option to acquire Pionyr Immunotherapeutics Inc., consisting of the acquisition by Gilead of a 49.9% equity interest in Pionyr for $275 million, an option for Gilead to acquire the remaining equity interests of Pionyr for $315 million, and up to $1.15 billion of potential future milestone payments to Pionyr equityholders
its $1.55 billion exclusive option to acquire Tizona Therapeutics, Inc., consisting of the acquisition by Gilead of a 49.9% equity interest in Tizona for $300 million, and an option for Gilead to acquire the remaining equity interests of Tizona for up to $1.25 billion of potential option fees and future milestone payments to Tizona equityholder
its $30 million PIPE investment in Gristone Oncology, Inc. (Nasdaq: GRTS) in connection with a collaboration, option and license agreement
TPG in its acquisition of Entertainment Partners*
Altamont Capital Partners in:
its carve-out acquisition of Publicis Healthcare Solutions*
• its sale of OMNIPLEX Worldwide Services Corporation to Constellis*

*Representation completed prior to joining Gunderson Dettmer.

General Corporate Counseling and Venture Financings

Moonwalk Biosciences with its formation and $57 million Series A Financing
Radar Therapeutics in its $13.4 million Series Seed financing
BillionToOne in its $130 million Series D financing, $125 million Series C financing, $48.5 million equity and $35 million debt financing
Alamar Biosciences in its $128 million Series C financing, $80 million Series B financing and spin-out of Attovia Therapeutics
Neuron23 in its $100 million Series C financing
Ancora Biotech LLC in its formation and $60 million Series A financing co-lead by Lightspeed Venture Partners and SR One
Star Therapeutics LLC in its $90 million Series C financing led by Sofinnova and spin-out of Electra Therapeutics
Electra Therapeutics in its $84 million Series B financing
Pro Shop its formation, $20 million Series A financing and partnership with the PGA Tour
Imply Data in its $100 million Series D financing

Growth Equity

Healthquest Capital in its investment in American Oncology Network in connection with American Oncology Network’s up-C reorganization and de-SPAC transaction
PFM Health Sciences as lead investor in Metagenomi’s $175 million Series B financing
Sixth Street Partners as lead investor in the $830 million growth equity financing in Caris Life Sciences*
Silver Lake Partners in its investment in Stripe*
Silver Lake Partners in its $400 million growth equity investment in EverCommerce*

Mergers & Acquisitions

TeneoTwo in its sale, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, to Astazeneca for up to $1.27 billion
Miroculus in its sale to Integra Biosciences
Gilead Sciences*, Inc. in:
its $1.74 billion exclusive option to acquire Pionyr Immunotherapeutics Inc., consisting of the acquisition by Gilead of a 49.9% equity interest in Pionyr for $275 million, an option for Gilead to acquire the remaining equity interests of Pionyr for $315 million, and up to $1.15 billion of potential future milestone payments to Pionyr equityholders
its $1.55 billion exclusive option to acquire Tizona Therapeutics, Inc., consisting of the acquisition by Gilead of a 49.9% equity interest in Tizona for $300 million, and an option for Gilead to acquire the remaining equity interests of Tizona for up to $1.25 billion of potential option fees and future milestone payments to Tizona equityholder
its $30 million PIPE investment in Gristone Oncology, Inc. (Nasdaq: GRTS) in connection with a collaboration, option and license agreement
TPG in its acquisition of Entertainment Partners*
Altamont Capital Partners in:
its carve-out acquisition of Publicis Healthcare Solutions*
• its sale of OMNIPLEX Worldwide Services Corporation to Constellis*

*Representation completed prior to joining Gunderson Dettmer.